PRAI (PrivaseaAI) fluctuates by 41.0% in 24 hours: Driven by increased trading volume and community trading signals
Bitget Pulse2026/04/09 01:01Volatility Overview
In the past 24 hours, PRAI's price reached a low of $0.00139 and a high of $0.00196, with the current price at $0.00193, registering a price swing of 41.0%. The 24-hour trading volume is approximately $129,000, with a market capitalization of about $305,000 and a circulating supply of around 206 million tokens.
Brief Analysis of Abnormal Fluctuations
- 24-hour trading volume expanded to $129,000 (mainly contributed by platforms such as MEXC), representing an 18% decrease from the previous day but still remaining active, supporting short-term price volatility.
- No official announcements, large on-chain whale transactions, or major news events observed; active trading signal posts on X platform, such as Finora AI's 1H chart analysis published on the evening of April 8, which predicted a continued price increase to $0.00180.
Market Views and Outlook
The mainstream sentiment on X is bullish, with AI trading tools optimistic about a short-term rebound to around $0.00180, but emphasizing the need to confirm support at $0.00164; otherwise, sentiment could turn bearish towards $0.00140. Analysts remind that small-cap tokens carry high risk, show great volatility, and lack obvious fundamental catalysts.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Fed Officials Turn Hawkish: Daly Says Supply Shocks Should No Longer Be "Wait-and-See," Hammack Suggests More Aggressive Rate Hikes May Be Needed if Inflation Expectations Become Entrenched
San Francisco Fed President Daly stated that the traditional "wait and see" approach to supply-side shocks has been abandoned, noting that businesses in her district are tending to pass rising costs on to consumers and that current inflation risks are "skewed fully to the upside." Cleveland Fed President Hammack said that once the public forms an "inflationary mindset," the difficulty of monetary policy regulation will increase significantly, and the required interest rate hikes will then exceed expectations.
Australian Dollar crumbles as job losses shatter RBA rate hike hopes
Over $10 billion in market value evaporated in four trading days as CoreWeave (CRWV.US) debt risks trigger sell-off, but Deutsche Bank sees it as a buying opportunity
Deutsche Bank believes that the recent sell-off of CoreWeave lacks sufficient company fundamentals to justify it, and the sharp price correction has instead created a buying opportunity for investors.
Crypto prices
More
